Astellas Pharma (OTCMKTS:ALPMY) Reaches New 52-Week High – Here’s Why

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) reached a new 52-week high on Thursday. The company traded as high as $17.43 and last traded at $17.30, with a volume of 6,141 shares trading hands. The stock had previously closed at $16.96.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Read Our Latest Stock Report on Astellas Pharma

Astellas Pharma Stock Up 1.8%

The company’s 50-day moving average is $15.38 and its 200 day moving average is $14.86. The company has a market capitalization of $31.25 billion, a PE ratio of 12.66 and a beta of 0.06. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.93 and a current ratio of 1.20.

Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.06). The firm had revenue of $3.98 billion during the quarter, compared to analysts’ expectations of $3.79 billion. Astellas Pharma had a return on equity of 26.13% and a net margin of 16.18%. As a group, analysts anticipate that Astellas Pharma Inc. will post 1.40 EPS for the current year.

Astellas Pharma Company Profile

(Get Free Report)

Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.

Recommended Stories

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.